Proactive Investors - Run By Investors For Investors

CytoDyn adds new talent to its management team

CytoDyn Inc (OTCMKST:CYDY) CEO Dr Nader Pourhassan and Dr Richard Pestell tell Proactive Investors the biotech has added two senior executives to its management team as it seeks regulatory approval of its flagship drug leronlimab (PRO 140) to treat cancer and HIV.

Dr Pestell added more insights and color into CytoDyn's recent announcement about beginning pre-clinical studies with leronlimab to treat Non-Alcoholic Steatohepatitis (NASH).

 
View full CYDY profile View Profile

CytoDyn Timeline

Copyright © Proactiveinvestors.com, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use